Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RARE
stocks logo

RARE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
188.05M
+14.05%
-1.203
-13.46%
172.08M
+23.54%
-1.415
-9.87%
186.85M
+12.22%
-1.262
+7.84%
Estimates Revision
The market is revising Downward the revenue expectations for Ultragenyx Pharmaceutical Inc. (RARE) for FY2025, with the revenue forecasts being adjusted by -0.39% over the past three months. During the same period, the stock price has changed by 14.83%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.39%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+12.64%
In Past 3 Month
Stock Price
Go Up
up Image
+14.83%
In Past 3 Month
Wall Street analysts forecast RARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RARE is 77.08 USD with a low forecast of 35.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast RARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RARE is 77.08 USD with a low forecast of 35.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 36.540
sliders
Low
35.00
Averages
77.08
High
125.00
Current: 36.540
sliders
Low
35.00
Averages
77.08
High
125.00
Barclays
Gena Wang
Overweight
downgrade
$81 -> $50
2025-11-24
Reason
Barclays
Gena Wang
Price Target
$81 -> $50
2025-11-24
downgrade
Overweight
Reason
Barclays analyst Gena Wang lowered the firm's price target on Ultragenyx to $50 from $81 and keeps an Overweight rating on the shares. The firm dropped the price target following analysis on the setrusumab COSMIC study. It still sees an over 70% chance of a positive study.
TD Cowen
Buy
downgrade
$86 -> $75
2025-11-05
Reason
TD Cowen
Price Target
$86 -> $75
2025-11-05
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on Ultragenyx to $75 from $86 and keeps a Buy rating on the shares. The firm said Crysvita Q3 revenues beat, Dojolvi in line, and total revenues were light. FY25 guidance and FY27 profitability reaffirmed.
BofA
Buy
downgrade
$79 -> $74
2025-10-22
Reason
BofA
Price Target
$79 -> $74
2025-10-22
downgrade
Buy
Reason
BofA lowered the firm's price target on Ultragenyx to $74 from $79 and keeps a Buy rating on the shares. The firm adjusted targets among its small-to-mid cap biotech coverage as part of a Q3 earnings preview for the group.
Canaccord
Whitney Ijem
Buy
downgrade
$136 -> $128
2025-08-08
Reason
Canaccord
Whitney Ijem
Price Target
$136 -> $128
2025-08-08
downgrade
Buy
Reason
Canaccord analyst Whitney Ijem lowered the firm's price target on Ultragenyx to $128 from $136 and keeps a Buy rating on the shares. The firm said the 2Q25 earnings report delivered a top- and bottom line beat with continued global demand for the company's commercial franchises; FY25 guidance and outlook for 2027 full year GAAP profitability reaffirmed.
H.C. Wainwright
Buy
initiated
$80
2025-07-28
Reason
H.C. Wainwright
Price Target
$80
2025-07-28
initiated
Buy
Reason
H.C. Wainwright assumed coverage of Ultragenyx with a Buy rating and $80 price target. The firm sees an attractive buying opportunity with the shares down 35% year-to-date. The Orbit trial did not fail and the final top-line result is risk-mitigated and should deliver favorable data, the analyst tells investors in a research note.
Morgan Stanley
Overweight
to
NULL
downgrade
$65 -> $55
2025-07-14
Reason
Morgan Stanley
Price Target
$65 -> $55
2025-07-14
downgrade
Overweight
to
NULL
Reason
Morgan Stanley lowered the firm's price target on Ultragenyx to $55 from $65 and keeps an Overweight rating on the shares. Ultragenyx's setrusumab strategy for osteogenesis imperfecta is scientifically supported and the chemistry, manufacturing and controls issues for UX111 are believed to be solvable, though these setbacks have heightened clinical and regulatory uncertainty, the analyst tells investors in a research note. The firm sees the market's reaction to the setrusumab update as overdone, with further pressure expected from the complete response letter in the near-term.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Ultragenyx Pharmaceutical Inc (RARE.O) is -7.39, compared to its 5-year average forward P/E of -9.45. For a more detailed relative valuation and DCF analysis to assess Ultragenyx Pharmaceutical Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.45
Current PE
-7.39
Overvalued PE
-3.82
Undervalued PE
-15.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-9.96
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-3.89
Undervalued EV/EBITDA
-16.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.19
Current PS
0.00
Overvalued PS
16.63
Undervalued PS
3.75
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 209.45% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 209.45% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

RARE News & Events

Events Timeline

(ET)
2025-11-04
17:38:47
Ultragenyx divests another 25% of Crysvita royalty stake for $400 million
select
2025-11-04
16:13:27
Ultragenyx confirms 2025 revenue forecast of $640M-$670M, aligning with consensus of $657.39M
select
2025-11-04
16:13:01
Ultragenyx Announces Q3 Earnings Per Share of $1.81, Exceeding Consensus Estimate of $1.21
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.0
11-30Yahoo Finance
Ultragenyx Stock Soars Following FDA News: Are Their Valuations Justified for 2025?

  • Stock Performance: Ultragenyx Pharmaceutical's stock has experienced volatility, with a recent 3.5% increase over the past week, but a decline of 1.2% over the past month and 27.0% over the last year, influenced by FDA updates and clinical developments.

  • Valuation Insights: A Discounted Cash Flow (DCF) analysis indicates that Ultragenyx is undervalued by 89.0%, with an estimated intrinsic value of $315.37 per share, despite current trading prices suggesting significant undervaluation.

  • Price-to-Sales Ratio: The company has a Price-to-Sales (P/S) ratio of 5.31x, which is lower than the industry average of 12.85x, suggesting it may be overvalued based on this metric, with a tailored Fair Ratio of 2.29x.

  • Narratives in Investing: Investors are encouraged to create personal narratives about Ultragenyx's future, linking their expectations for growth and risks to fair value estimates, which can vary widely among investors based on differing outlooks.

[object Object]
Preview
2.0
11-28NASDAQ.COM
Ultragenyx Pharmaceutical Surpasses 200-Day Moving Average - Positive Outlook for RARE

  • 52 Week Range: RARE's stock has a 52-week low of $25.81 and a high of $50, with the last trade recorded at $34.39.

  • Market Analysis: The article mentions other stocks that have recently crossed above their 200-day moving average, indicating potential market movements.

  • Author's Perspective: The views expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.

  • Stock Performance Insight: The information provided highlights the current performance and volatility of RARE's stock within the specified time frame.

[object Object]
Preview
1.0
11-25Newsfilter
Ultragenyx to Participate in Two Upcoming Investor Conferences
  • Investor Conference Participation: Ultragenyx Pharmaceutical Inc. will participate in Citi's 2025 Global Healthcare Conference on December 2, 2025, where Chief Medical Officer Eric Crombez will engage in a fireside chat, aiming to enhance the company's visibility among investors.
  • Industry Networking Opportunity: Following this, Ultragenyx will attend the 8th Annual Evercore ISI Healthcare Conference on December 3, 2025, further showcasing its innovative capabilities in the rare disease treatment sector.
  • Webcast Accessibility: The live and archived webcasts of both fireside chats will be available on the company's website, ensuring that investors can access the latest information at their convenience, thereby enhancing transparency and investor trust.
  • Strategic Development Focus: Ultragenyx is committed to developing innovative therapies for serious rare diseases, and its participation in these conferences reflects its active engagement in the industry and emphasis on investor relations, aiming to drive future funding support and market recognition.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ultragenyx Pharmaceutical Inc (RARE) stock price today?

The current price of RARE is 36.54 USD — it has increased 0.25 % in the last trading day.

arrow icon

What is Ultragenyx Pharmaceutical Inc (RARE)'s business?

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.

arrow icon

What is the price predicton of RARE Stock?

Wall Street analysts forecast RARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RARE is 77.08 USD with a low forecast of 35.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ultragenyx Pharmaceutical Inc (RARE)'s revenue for the last quarter?

Ultragenyx Pharmaceutical Inc revenue for the last quarter amounts to 159.93M USD, increased 14.65 % YoY.

arrow icon

What is Ultragenyx Pharmaceutical Inc (RARE)'s earnings per share (EPS) for the last quarter?

Ultragenyx Pharmaceutical Inc. EPS for the last quarter amounts to -1.81 USD, increased 29.29 % YoY.

arrow icon

What changes have occurred in the market's expectations for Ultragenyx Pharmaceutical Inc (RARE)'s fundamentals?

The market is revising Downward the revenue expectations for Ultragenyx Pharmaceutical Inc. (RARE) for FY2025, with the revenue forecasts being adjusted by -0.39% over the past three months. During the same period, the stock price has changed by 14.83%.
arrow icon

How many employees does Ultragenyx Pharmaceutical Inc (RARE). have?

Ultragenyx Pharmaceutical Inc (RARE) has 1294 emplpoyees as of December 05 2025.

arrow icon

What is Ultragenyx Pharmaceutical Inc (RARE) market cap?

Today RARE has the market capitalization of 3.52B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free